<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cefozopran (CZOP) and <z:chebi fb="0" ids="2637">amikacin</z:chebi> (AMK) were used concomitantly to treat <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated by <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 103 subjects were evaluated, and the <z:hpo ids='HP_0000001'>all</z:hpo> over efficacy rate was 69.9% </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0002488'>Acute leukemia</z:hpo> was found in the largest number of patient, 57, followed by 29 cases of malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 7 cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>By type of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, patients having unknown origin were the largest in number, being 66, and the efficacy rate was 71.2% </plain></SENT>
<SENT sid="4" pm="."><plain>The efficacy rates for <z:hpo ids='HP_0100806'>sepsis</z:hpo>, <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> were 42.9% (7 cases), 71.4% (14 cases) and 90% (10 cases) respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy rates by neutrophil counts before administration of CZOP and AMK and at 1 week after administration were both 53.3% in the group of less than 100/microliter, both 60% in the group of less than 500/microliter </plain></SENT>
<SENT sid="6" pm="."><plain>The efficacy rate by neutrophil counts at 1 week after administration was 58.6% in the group of less than 100/microliter </plain></SENT>
<SENT sid="7" pm="."><plain>The efficacy rate was 75.4% in the group of granulocyte colony stimulating factor (G-CSF) concomitant usage, and 61.9% in the group of non-concomitant usage group </plain></SENT>
<SENT sid="8" pm="."><plain>The efficacy rates by serum albumin levels before administration of CZOP and AMK and at 1 week after administration were both 92.9% in the group of over than 4 g/dl, both 50% in the group of less than 3 g/dl </plain></SENT>
<SENT sid="9" pm="."><plain>Concomitant treatment with CZOP and AMK exhibited a high level of safety and efficacy rates in <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated by <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> </plain></SENT>
</text></document>